April 25, 2024 03:00 PM EDT
FDA+
Marketing

FDA re­vis­es guid­ance on biosim­i­lar pro­mo­tion­al la­bels and ad­ver­tis­ing

Beth Snyder Bulik

Senior Editor

Fol­low­ing a re­cent move to ask Con­gress to elim­i­nate the in­ter­change­abil­i­ty des­ig­na­tion for biosim­i­lars, the FDA on Wednes­day pro­posed up­dat­ed guid­ance on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

A service from the Financial Times